Thus, 5 out of 28 HER2-positive tumors and 1 out of the remaining 62 HER2-negative tumors developed metastatic disease during the follow-up (x2 = 8.18; p = 0.004). The gene discussed is ERBB2; the disease is metastatic neoplasm.